based differences in body weight. Genetically based variations in pharmacodynamic and pharmacokinetic responses to numerous drugs have been demonstrated, 3, 4 lending credence to the possibility that appropriate dosing of fibrinolytics might require adjustment on the basis of ethnicity. Importantly, excesses of these agents have been closely associated with increased overall bleeding complications, particularly intracranial hemorrhage, 5 providing impetus to further explore this dose issue in another completely Asian patient group.
The trial hypothesis (principal end point) was that the rate of 90-minute posttreatment infarct-related artery (IRA) patency (flow grades 2 or 3 according to the Thrombolysis in Myocardial Infarction [TIMI] grading system) 6 would be 20 absolute percent units higher after reduced dose recombinant tPA (rtPA) than stanReports chiefly from Japan have suggested that Asian patients with acute myocardial infarction treated with tissue plasminogen activators (tPA) achieve favorable results after total doses substantially lower than those routinely used in European and North American patients. 1,2 Dosages used have been far lower than might be expected if simply the result of population-Background Reports from Japan suggest effective myocardial infarction (MI) treatment in Asian patients with much lower doses of tissue plasminogen activators (tPA) than used in European and American regimens. Because increasing doses of fibrinolytics lead to increased bleeding complications, identification of patients who respond to reduced doses is of importance. We conducted a trial in the People's Republic of China in which reduced-dose recombinant tPA was compared with the standard local therapy, urokinase.
Methods Four hundred patients with acute MI within 12 hours of symptom onset were to be randomized to an 8-mg bolus of recombinant tPA followed by a 42-mg 90-minute infusion or 1.5 million units of urokinase as a 30-minute infusion. Patients received aspirin and heparin and underwent angiography to determine infarct artery patency 90 minutes after the start of therapy.
Results
The Data and Safety Monitoring Board recommended premature termination after 342 patients were recruited.
Infarct artery patency (grade 2 or 3) occurred in 79% of patients receiving recombinant tPA and in 53% of patients receiving urokinase (P < .001); Thombolysis in Myocardial Infarction (TIMI) grade 3 flow was 48% and 28%, respectively (P < .001). The higher-patency-rate recombinant tPA growth had better posttreatment left ventricular ejection fractions, 58.6% versus 54.7%, P < .01. Adverse events were infrequent and not significantly different in the 2 groups.
Conclusions
This study confirms that a substantially lower dose of recombinant tPA is effective in Asian patients compared with that required in Western patients even after consideration of body weight. Specific dose-response studies should be performed with fibrinolytic regimens to avoid overdosage with its attendant risks of excess bleeding. ( 
Methods
We performed an open-label randomized comparison of 50 mg of rtPA (Actilyse, Boehringer-Ingelheim, Ingelheim, Germany) versus the standard reperfusion regimen used in the People's Republic of China, UK (Nanjing Medical University Pharmaceuticals, People's Republic of China). The rtPA was administered as an 8-mg bolus followed by an infusion of 42 mg over the next 90 minutes, whereas the UK was given as 1.5 million units infused over 30 minutes. All patients provided written consent before being randomized into the trial. Inclusion criteria were as follows: pain onset within 12 hours, symptom duration >30 minutes, ST-segment elevation ≥0.1 mV in 2 or more limb leads or ≥0.2 mV in 2 or more contiguous precordial leads. Exclusion criteria were >70 years old, previous cerebrovascular accident (CVA), active bleeding or bleeding diathesis, recent trauma, systolic blood pressure >170 or diastolic >110 at time of randomization, and cardiogenic shock unresponsive to vasopressors. All patients received oral aspirin (>300 mg immediately and during the first week and 50 mg daily thereafter). Unfractionated heparin was given as a 5000 IU intravenous bolus and titrated to a target activated partial thromboplastin time (aPTT) range of 2 to 2.5 times control. aPTTs were assessed with a bedside monitoring device (Hemochron Jr, International Technidyne, Edison, NJ). Study sites are listed in Appendix A.
All angiographic interpretations were performed at a core laboratory (George Washington University) by experienced investigators who were blinded to treatment assignment. Chisquare tests were used to compare frequencies of categorical variables. Continuous variables were compared with Student t tests; all P values were 2 tailed. To assess the predictors of patency (TIMI grade 3 alone and TIMI grade 2/3), multivariate logistic regressions were performed with the following covariates included in the model: weight, height, time to treatment, treatment given, age, sex, smoking status, hypertension, diabetes, previous infarction, and location of infarction. To detect a 20% superiority in the principal patency end point with power = 0.9 and α = .05, a sample size of 200 patients per group was needed. An independent Data and Safety Monitoring Committee (DSMB) had oversight of the trial (Appendix B).
Results
On the recommendation of the DSMB, the trial was terminated prematurely after 342 patients had been enrolled because the principal end point had been demonstrated.
Common baseline variables for the 2 treatment groups were similar (Table I) . Patients on average were 59 years old and weighed 69 kg, and 45% were smokers.
Ninety-minute protocol coronary angiograms were obtained in 330 of 342 (96%) patients. The 12 exceptions (5 rtPA, 7 UK) were due to the following: clinical circumstances precluding the angiogram (n = 1), the film was technically inadequate (n = 4), or the IRA could not be identified with certainty (n = 7). Seventy percent of patients had a left ventricular angiogram performed during the same procedure of adequate quality for quantitative analysis.
Ninety minutes after the start of therapy, 79% of patients receiving low-dose rtPA had a patent IRA (TIMI grade 2 or 3) versus 53% of UK recipients (P < .001). Corresponding rates of TIMI grade 3 were 48% and 28%, respectively (P < .001) ( Table II) . The only predictor of patency noted in the logistic regression models was rtPA administration, which had an odds ratio (OR) of 2. (Table III) . The median hemoglobin drop from admission to discharge (nadir value) was 1.0 g/dL with rtPA and 0.8 g/dL for UK (P not significant). Four rtPA and 2 UK patients received blood transfusions. One patient in each group had a stroke, both considered to be hemorrhagic in origin. Additional clinical outcomes are presented in Table IV . Left ventricular ejection fraction after therapy was 58.6% (±11.4) in the rtPA group and 54.7% (±12.7) after UK (P < .01). Overall mortality at 30 days was 4.5% (6% rtPA, 3% UK; P = .28). The 30-day mortality rate according to 90-minute TIMI flow grade was 0.8% for TIMI grade 3, 2.3% for TIMI grade 2, and 9.8% for TIMI grade 0 or 1 (P = .003).
Discussion
The observation that Asian patients with an infarct treated with rtPA achieve patency rates equivalent to those reported in Western countries but at considerably lower doses is confirmed in the current study. It was further observed, consistent with previous reports on the results with streptokinase and UK, 7, 8 that the tPAs are superior to these other agents in promoting IRA patency after myocardial infarction.
This angiographic study does not identify a physiologic basis for the apparent population-based difference in response to plasminogen activators, but other genetic pool-based subgroups have also been identified as having responses different from the Euro-American groups studied in the largest myocardial infarction trials. 9, 10 Population-based differences in plasminogen activator antigen, baseline tPA and plasminogen activator inhibitor-I levels, and phenotypes for plasminogen have also been demonstrated. [11] [12] [13] [14] The observed patterns in this and previous studies cannot be explained by differences in body weight. In the 41,000-patient Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial, the mean patient weight was 78 kg. 15 In the current study the mean patient weight was 69 kg, only lower by 11.5%, whereas the dose of rtPA was reduced by 50%.
A chief limitation of this study is the absence of a formal dose-response interrogation because a fixed reduced dose was preselected. The results achieved with 50 mg of rtPA are not evidence that additional activator might not further enhance early patency rates or clinical benefits. The observed rate of TIMI grade 3 flow in this study is modestly lower than that reported with "full-dose" thrombolytic therapy in most recent Western studies. 16 Importantly, however, the safety profile of higher doses in Asian patients is not known nor are the side effect data in the current study definitive because the sample size was not chosen on the basis of adverse event frequency. Furthermore, it should be noted that because this was the first evaluation of this regimen in this population, caution regarding stroke risks led to excluding elderly patients (ie, >70 years old) from the trial. Thus the elderly's response to this type of regimen remains to be determined. Recent experiences suggesting enhancement of fibrinolytic activity by the adjunctive use of platelet glycoprotein receptor antagonists and direct thrombin inhibitors 17, 18 postdate the conduct of this trial. It would be of interest and importance to evaluate the appropriate dosing of such reperfusion combinations in a patient group similar to that studied in the TPA/Urokinase Comparisons in China (TUCC) trial.
Conclusion
In an exclusively Chinese acute myocardial infarction patient population, a reduced dose of only 50 mg of rtPA produced infarct artery patency, TIMI grade 2 or 3 of 79%, equivalent to rates achieved with 100 mg in Western populations. Furthermore, this regimen was superior to standard-dose UK therapy both in patency and resultant left ventricular function without producing significantly augmented rates of bleeding complica- Table IV . Clinical outcomes tions. Current and future reperfusion regimens should be evaluated for their dose-response effects as a function of the target population and further investigation into the mechanisms of variable responses to fibrinolytics deserves further attention.
